Posts Tagged ‘R&D’

Alcon Turnaround Has Novartis Exploring Spin-off

In announcing that Novartis AG is exploring spinning off its Alcon eye-care business, Novartis CEO Joseph Jimenez acknowledged that Alcon has made progress in the past year in executing its turnaround plan under CEO Mike Ball. Novartis revealed it is exploring options for Alcon that include spinning it off, issuing an IPO or keeping it,…

Read More

Is Trump Opening New Front in War on Drug Prices?

Pharma executives were beaming as their stock prices soared in the days after Donald Trump’s poll-defying victory, and their sentiments rose even higher with the defeat of a California ballot initiative that would have instituted price controls on state-purchased drugs. Then Trump held his first post-election press conference last week, saying that pharma was “getting…

Read More

Abbott Medical Optics Points to Leadership Position

Over the past year, Abbott Medical Optics (AMO) has established a leading share position in the US PC-IOL market, driven by the new low-add-power Tecnis Multifocal IOLs. Outside the US, the early success of the Tecnis Symfony Extended Range of Vision IOL has also contributed to market share gains. A large European multicenter post-market study…

Read More

Tom Frinzi’s Plans for AMO & Ophthalmology

Ophthalmology veteran Tom Frinzi joins OISTV to share his reasons for joining Abbott Medical Optics and what the company may be planning in coming years. Video Highlights 00:32 – What brought you to AMO? 1:20 – What are the three Ps? 2:02 – Is there a formula for leading any a company? 3:51 – How…

Read More

MIGS Market Just Beginning to Hit Its Stride

Glaucoma is the second leading cause of blindness worldwide, and the number of people with some form of glaucoma is expected to rise to 80 million by 2020, said Ike Ahmed, MD. “This is a $6 billion market that’s continuing to grow, but our current therapies are suboptimal,” he said, adding adherence, side effects, and…

Read More

Yeu on the Success of the Spotlight on the Premium Channel

Elizabeth Yeu, MD, led the “Spotlight on the Premium Channel” discussion at OIS@ASCRS 2016. In her session, representatives from AcuFocus, Bausch + Lomb, Abbott Medical Optics and Alcon shared information about their current and future pipelines. Dr. Yeu serves as a Corneal, Cataract and Refractive Surgeon at Virginia Eye Consultant and dedicates her time to…

Read More

OISPodcast@ASCRS – Meury: Why Allergan Won’t Miss a Beat in Building Ophthalmology Franchise

OISPodcast@ASCRS - Meury: Why Allergan Won’t Miss a Beat in Building Ophthalmology Franchise - OIS Podcast - Eye On Innovation

Deals sometime collapse, but they usually don’t get hit with a smart bomb from the Department of Treasury. Allergan, newly single following the break up with Pfizer, is looking to build a business in ophthalmology. Bill Meury, the newly named chief commercial officer of Allergan, talks about the non-Pfizer deal, Allergan’s ophthalmology pipeline and where…

Read More

Allotex

OIS@ASCRS - Companies to Watch - Allotex 2016

The driving force behind Allotex was the observation that the potential interest in synthetic corneal inlay technology was being dampened by the persistent biocompatibility issue. Recognizing the many technological changes that have occurred since Barraquer’s early pioneering epikeratophakia work, the company was established to develop human allograft inlays and onlays to satisfy a growing market…

Read More

Masters of The Universe

The day concluded with the Masters of the Universe panel where AcuFocus executive chairman Jim Mazzo led a discussion between Link and executives from Abbott Medical Optics, Alcon, Allergan, Bausch & Lomb, Carl Zeiss Meditec, and Johnson & Johnson Vision Care. Mazzo introduced the panel – and the notion of industry consolidation – with a…

Read More

The “Post-Game Wrap-Up” with OIS@ASCRS Co-Chairs

The “Post-Game Wrap-Up” with OIS@ASCRS Co-Chairs - OIS@ASCRS 2016

OIS co-chairs and VCs Emmett Cunningham, MD, Gil Kliman, MD, and Bill Link, PhD, sit down with OISTV to review the highlights of the May 5 OIS@ASCRS in New Orleans. Topics include the purpose for OIS, plans for future meetings, and advances in ophthalmology treatments. Video Timestamp: 00:52 – The benefit of the breakout sessions.…

Read More

What are Allergan’s Next Steps?

What’s Allergan’s Next Steps? - OIS Podcast

The near merger between Pfizer and Allergan clearly was financially motivated. But the deal promised to bring Pfizer’s firepower to ophthalmology. What does the annulment of the deal mean for our sector? Podcast Guest Brent Saunders Dr. Gil Kliman leads the medical device investment team at InterWest Partners and invests in a broad array of…

Read More